To evaluate the role of ultrasound in prenatal diagnosis of congenital anomalies of kidney and urinary system in third trimester of pregnancy.
Primay outcomes:
To determine incidence of congenital anomalies in kidney and urinary system in Third Timerter by ultrasound.

开始日期2024-07-01

申办/合作机构

Assiut University

NCT06349668 / Recruiting临床3期IIT

Effekten av Intratekalt Morfin Eller intravenöst Lidokain på Postoperativ återhämtning Efter Robotassisterad övre Urologisk Kirurgi. Randomiserad Assessor-blindad Multicenterstudie. SMILe: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:
Is the decrease in wellbeing as quantified by the patient-centered outcome scale "Quality of Recovery 15" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia?
Does spinal analgesia result in improved recovery as quantified by QoR-15 at POD 7, the incidence of postoperative pain at rest and at mobilization, nausea and vomiting, the need for opioid analgesics, time out-of-bed, length of stay and the incidence of complications?
Does spinal analgesia increase workload in the OR, as quantified by time from arrival in the OR to start of surgery?
Does spinal analgesia result in an increased incidence of hypotension and cardiac dysfunction during surgery, as well as an increased incidence of pruritus after surgery?
Participants will be randomized to receive either spinal analgesia with bupivacaine and morphine preoperatively or an intravenous infusion with lidocaine intraoperatively.
QoR-15 and other markers of recovery will be registered using structured interviews preoperatively, at POD1 and POD7. In addition, patients will record pain at rest and at mobilization three times daily in a diary.
In a subgroup of patients advanced hemodynamic parameters will be recorded using pulse-contour analysis before, during and after surgery. Blood samples will also be collected in these patients at fixed intervals and analyzed for amongst others inflammation and cardiac dysfunction.

开始日期2024-04-09

申办/合作机构-

ChiCTR2400081850 / SuspendedIIT

Tubularized Bladder Mucosa Method for Treating Primary Vesicoureteral Reflux in Children

开始日期2024-03-25

申办/合作机构-

100 项与膀胱输尿管返流相关的临床结果

登录后查看更多信息

100 项与膀胱输尿管返流相关的转化医学

登录后查看更多信息

0 项与膀胱输尿管返流相关的专利（医药）

登录后查看更多信息

9,737

项与膀胱输尿管返流相关的文献（医药）

2024-12-01·The French Journal of Urology

Lower urinary tract involvement in Ehlers-Danlos and Joint Hypermobility syndromes: Review of the literature

Article

作者: Brierre, Thibaut ; Boileau, Adrien ; Castel-Lacanal, Évelyne ; Gamé, Xavier ; Soulié, Michel

INTRODUCTIONEhlers-Danlos syndrome (EDS) and Joint Hypermobility syndrome (JHS) are still poorly understood, with a prevalence of 1/5000 for EDS and 1/500 for JHS. They are characterized by multisystem involvement. Urological involvement has been little studied. The aim was to carry out a review of the literature on the urological involvement of EDS and JHS.METHODA review of the literature was carried out using the following databases: Pubmed, Canadian Hospitals and EMBASE. Search terms were "Ehlers-Danlos" or "Joint Hypermobility" associated with "Urology", "Bladder", "Pelvic Organ Prolapse", "Urinary Retention", "Leak", "Leakage", "Urinary Incontinence", "Urinary Tract Infection" and "Urdodynamic", no filters were added.RESULTSSeventy-three articles were included for a total of 259 found. The prevalence of urinary incontinence in EDS is estimated at 50-60%, and that of pelvic organ prolapse (POP) at 29-75%. Bladder diverticula are also frequently reported. For JHS, the prevalence of urinary incontinence is estimated between 40 and 73%, that of POP increased with 73% of stage greater than 2, g-JHS patients are almost 3 times more affected by prolapses (OR=2.37) which seem more severe. Patients with vesicoureteral reflux, most often severe, are more affected by joint hypermobility (OR=2.79). Few studies have been carried out on urological assessment and treatment modalities.CONCLUSIONEDS patients often have urinary incontinence, pelvic organ prolapse or bladder diverticula. JHS patients frequently have urinary incontinence, pelvic organ prolapse and vesicoureteral reflux.

2024-12-01·Radiology Case Reports

Bilateral ureteral obstruction after open ureteral reimplantation in a 3-year-old patient with Williams Beuren syndrome

Article

作者: Chang, Barry ; Rainey, Shane C

Vesicoureteral reflux (VUR) is a common urological problem in the pediatric population and can be corrected by ureteral reimplantation in severe or persistent cases. This procedure is generally well tolerated, although complications, including ureteral obstruction, may occur in the postoperative period. We present a rare case of a 3-year-old with Williams Beuren syndrome who underwent bilateral ureteral reimplantation for VUR and subsequently developed bilateral ureteral obstruction with acute renal failure requiring nephrostomy tube placement within 48 hours of surgery.

2024-12-01·Pediatric Nephrology

Risk factors and outcome of BK polyomavirus infection in pediatric kidney transplantation

Article

作者: Chen, Jing ; Fang, Xiaoyan ; Liu, Feng ; Shen, Qian ; Sun, Yubo ; Zhang, Zhiqing ; Wang, Chunyan ; Xu, Hong ; Lin, Fang ; Chen, Rui ; Zhai, Yihui

BACKGROUNDBK polyomavirus (BKV) infection is a critical complication hindering graft survival after kidney transplantation. We aimed to investigate the risk factors and outcome of BKV infection in pediatric kidney transplantation.METHODSThe clinical and follow-up data of pediatric kidney transplant recipients at the Children's Hospital of Fudan University from Jan 2015 to June 2023 were retrospectively analyzed.RESULTSA total of 217 patients were included in the study with mean follow-up time of 24.3 ± 19.9 months. The mean age at transplantation was 9.7 ± 4.2 years. The patient survival rate and graft survival rate were 98.2% and 96.8%, respectively. Twenty-nine patients (13.4%) developed BKV infection, which was detected at 5.8 ± 3.2 months after transplantation. Among these 29 patients with BKV infection, 8 patients (3.6%) developed BKV nephropathy (BKVN), which was diagnosed at 8.3 ± 2.9 months after transplantation, and 2 patients developed graft failure eventually. Compared with the non-BKV infection group (eGFR 76.7 ± 26.1 mL/min/1.73 m²) and BKV infection without BKVN group (eGFR 85.2 ± 23.8 mL/min/1.73 m²), BKVN group had lowest eGFR during follow-up (33.5 ± 11.0 ml/min/1.73 m², P < 0.001). Younger age at transplant (OR 0.850, 95%CI 0.762-0.948, P = 0.005), CAKUT disease of primary etiology (OR 2.890, 95%CI 1.200-6.961, P = 0.018), and CMV negative recipient serostatus before transplantation (OR 3.698, 95%CI 1.583-8.640, P = 0.003) were independent risk factors for BKV infection.CONCLUSIONSIncidence of BKV infection is quite high within 12 months after pediatric kidney transplantation and children with BKVN have poor graft function. Younger age at transplant, CAKUT disease, and CMV negative recipient serostatus before transplantation increase the risk of BKV infection after kidney transplantation.

项与膀胱输尿管返流相关的新闻（医药）

2023-10-11

·GlobeNewswire-Health Care

Teleflex Completes Acquisition of Palette Life Sciences

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Palette Life Sciences AB. The acquisition adds Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolio. Barrigel® is a Non-Animal Stabilized Hyaluronic Acid (NASHA) spacer designed to reduce radiation delivered to the rectum during prostate cancer radiation therapy, while increasing tumor control and patient quality of life.1 The Palette Life Sciences portfolio also includes Deflux® and Solesta®, which are NASHA based tissue bulking agents designed to treat pediatric vesicoureteral reflux and fecal incontinence, respectively. On July 26, Teleflex announced its entry into a definitive agreement to acquire Palette. Under the terms of the agreement, Teleflex acquired Palette for an upfront cash payment of $600 million at closing, with additional consideration of up to $50 million upon the achievement of certain commercial milestones. On a standalone basis, we continue to expect Palette net revenue to be approximately $56 million for 2023. The acquisition is expected to be approximately $0.25 dilutive to adjusted earnings per share (excluding non-recurring purchase accounting items and other acquisition and integration related costs) in 2023. For 2024, the transaction is expected to deliver a high-teens to low 20% revenue growth profile and be approximately $0.35 dilutive to adjusted earnings per share (excluding non-recurring purchase accounting items and other acquisition and integration related costs). The transaction is expected to be increasingly accretive to adjusted EPS, thereafter. About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift® and Weck® – trusted brands united by a common sense of purpose. References: Mariados NF, Orio PF, Schiffman Z, et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial. JAMA Oncol. 2023; e1-e8. The content above comes from the network. if any infringement, please contact us to modify.

并购放射疗法临床研究

2023-07-27

·医药观澜

6.5亿美元收购！这家械企囊获系列介入泌尿创新产品

▎药明康德内容团队报道7月26日消息，泰利福（Teleflex）公司宣布已达成最终协议，将以6亿美元的预付款收购Palette Life Sciences公司，并在交易完成时额外支付5000万美元。根据泰利福公司新闻稿，此次收购将扩大其介入泌尿学产品组合，包括可生物降解的直肠垫片等，以改善泌尿科和泌尿妇科疾病、结直肠疾病和放射肿瘤学手术患者的预后。该项收购预计将于2023年第四季度完成。截图来源：参考资料[1]Palette公司致力于发现临床已证实疗法的新应用以治疗不常见或难以治疗的疾病，旨在解决传统医疗公司经常忽视的患者需求。该公司的核心技术围绕着非动物源性稳定透明质酸（NASHA），这是一种稳定、温和的透明质酸，也是所有人体组织的普遍成分。这类材料具有适应性强、可定制、灵活的特性，且透明质酸是天然存在于人体的物质，其与人体的高度生物相容性使其成为理想的生物医学材料。NASHA在医疗行业已经有超过20年的应用历史。Palette公司的关键产品是一款名为Barrigel的NASHA间隔器，该产品旨在减少前列腺癌放射治疗期间在直肠的放射量，同时提高患者的生活质量。据悉，Barrigel易于成型，在经直肠超声上高度可见，且可生物降解，可在所有服务场所进行组装。该产品已经于2022年5月获得美国FDA批准上市，并已在澳大利亚和欧盟获批。此外，Palette公司的产品组合还包括基于NASHA的组织膨胀剂Deflux和Solesta，它们分别用于治疗儿童膀胱输尿管反流和大便失禁。泰利福是一家全球医疗技术提供商，其产品组合包括血管通路、介入心脏病学和放射学、麻醉、急诊医学、外科、泌尿学和呼吸护理等领域的解决方案。对于本次收购，泰利福公司董事长、总裁兼首席执行官Liam J. Kelly先生表示，泰利福专注于为发掘创新产品和技术，这些产品和技术可以有效地提高临床疗效、患者安全和舒适度，减少并发症并降低总体护理成本。收购Palette公司将使他们能够将令人兴奋的技术纳入介入泌尿科业务部门，并为泌尿科医生、放射肿瘤科医生和其他专家带来更多创新技术，对患者护理产生积极影响。参考资料：[1]Teleflex to Acquire Palette Life Sciences. Retrieved Jul 26 , 2023. From https://investors.teleflex.com/news/news-details/2023/Teleflex-to-Acquire-Palette-Life-Sciences/default.aspx[2]Palette公司官网. From https://www.palettelifesciences.com/nasha/本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

并购上市批准

2023-07-27

·NS Medical Devices

Teleflex agrees to purchase Palette Life Sciences for $650m

Through the acquisition, Teleflex will obtain Palette Life Sciences’ Barrigel non-animal stabilised hyaluronic acid (NASHA) spacer to its interventional urology portfolio, which is biodegradable, reversible, and offers one-step assembly in all sites Teleflex to acquire Palette Life Sciences. (Credit: Piron Guillaume on Unsplash) US-based medical device company Teleflex has agreed to purchase Palette Life Sciences for an upfront cash payment of $600m and up to $50m in commercial milestone payments. Palette Life Sciences is an integrated medical device company that provides a wide range of products and services for improving the patients’ quality of life. The company’s lead product, Barrigel, is a non-animal stabilised hyaluronic acid (NASHA) spacer, which has been approved in the US, Australia, and the EU. Palette’s portfolio also includes other NASHA-based tissue bulking agents, Deflux and Solesta to treat paediatric vesicoureteral reflux and faecal incontinence, respectively. The acquisition is expected to be completed in the fourth quarter of this year, subject to customary closing conditions, including receipt of certain regulatory approvals. Teleflex intends to finance the transaction using borrowings under its revolving credit facilities and available cash on hand. Teleflex chairman, president and CEO Liam Kelly said: “Teleflex is focused on deploying capital for innovative products and technologies that can meaningfully enhance clinical efficacy, patient safety and comfort, reduce complications, and lower the overall cost of care. “The acquisition of Palette Life Sciences will allow us to incorporate this exciting technology into our Interventional Urology business unit and bring urologists, radiation oncologists, and other specialists more innovative technologies that can positively impact patient care. “The transaction is consistent with our strategy to acquire assets that are accretive to Teleflex’s growth rate.” Teleflex said that the acquisition of Palette Life Sciences will expand its Interventional Urology portfolio, which includes the UroLift System. The transaction will add Palette’s NASHA spacer and tissue bulking products that improve urology and urogynecology disorders, colorectal conditions, and radiation oncology procedures. The Barrigel is a rectal spacer used for reducing the radiation delivery to the rectum during prostate cancer radiation therapy. It is an easily sculptable, highly visible on transrectal ultrasound (TRUS), biodegradable, reversible rectal spacer, that offers one-step assembly in all sites of service, said Teleflex. Kelly added: “We expect the acquisition will be immediately accretive to adjusted gross margin and will enhance our adjusted operating margin in the near term. We believe Palette Life Sciences will be a meaningful contributor to our growth in the coming years. “In 2024, we expect this business will achieve year-over-year revenue growth in the high-teens to low 20% range, which gives us further confidence in our ability to deliver on our 2023-2025 LRP financial objectives.”

并购上市批准放射疗法